YMAB Q1 EPS Estimate Reduced by Brookline Capital Management

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) – Equities researchers at Brookline Capital Management reduced their Q1 2025 EPS estimates for Y-mAbs Therapeutics in a research report issued on Tuesday, April 22nd. Brookline Capital Management analyst K. Dolliver now forecasts that the company will post earnings of ($0.22) per share for the quarter, down from their prior forecast of ($0.17). The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($0.65) per share. Brookline Capital Management also issued estimates for Y-mAbs Therapeutics’ Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.20) EPS and FY2025 earnings at ($0.93) EPS.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Tuesday, March 4th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). The firm had revenue of $26.50 million for the quarter, compared to analyst estimates of $26.70 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same quarter last year, the firm posted ($0.02) EPS.

YMAB has been the subject of several other reports. HC Wainwright decreased their price target on Y-mAbs Therapeutics from $22.00 to $12.00 and set a “buy” rating for the company in a report on Friday, March 21st. Truist Financial lowered their target price on shares of Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, March 5th. Morgan Stanley cut their price target on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating for the company in a report on Wednesday, March 5th. Wedbush reaffirmed an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a report on Monday, March 3rd. Finally, Bank of America downgraded Y-mAbs Therapeutics from a “neutral” rating to an “underperform” rating and set a $3.00 target price for the company. in a research note on Tuesday. Two research analysts have rated the stock with a sell rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.40.

Y-mAbs Therapeutics Stock Performance

Shares of Y-mAbs Therapeutics stock opened at $4.10 on Friday. The company’s fifty day moving average is $4.87 and its two-hundred day moving average is $8.19. Y-mAbs Therapeutics has a 1 year low of $3.84 and a 1 year high of $17.78. The company has a market capitalization of $185.39 million, a P/E ratio of -7.59 and a beta of 0.71.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Acorn Capital Advisors LLC bought a new stake in Y-mAbs Therapeutics in the 4th quarter valued at about $22,408,000. Caligan Partners LP increased its stake in shares of Y-mAbs Therapeutics by 47.9% in the fourth quarter. Caligan Partners LP now owns 1,767,982 shares of the company’s stock valued at $13,843,000 after purchasing an additional 572,729 shares during the period. Infinitum Asset Management LLC bought a new stake in shares of Y-mAbs Therapeutics during the fourth quarter valued at approximately $1,218,000. Paradigm Biocapital Advisors LP boosted its position in shares of Y-mAbs Therapeutics by 3.7% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 4,236,346 shares of the company’s stock worth $33,171,000 after buying an additional 150,000 shares during the period. Finally, Boothbay Fund Management LLC grew its holdings in Y-mAbs Therapeutics by 24.4% in the 4th quarter. Boothbay Fund Management LLC now owns 693,693 shares of the company’s stock worth $5,432,000 after buying an additional 136,264 shares in the last quarter. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 10,810 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $5.23, for a total transaction of $56,536.30. Following the transaction, the insider now owns 202,721 shares of the company’s stock, valued at $1,060,230.83. This trade represents a 5.06 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 22.50% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.